\chapter{Medications Targeting Underlying Mechanisms}
\label{ch:medications-mechanisms}

\section{Immune-Modulating Medications}
\label{sec:immune-medications}

\subsection{Low-Dose Naltrexone (LDN)}
% Mechanism of action
% Dosing protocols
% Evidence
% Side effects
% Patient selection

\subsection{Immunoglobulins (IVIG)}
% Rationale
% Clinical trials
% Costs and practicality
% Who might benefit

\subsection{Rituximab}
% B-cell depletion rationale
% Clinical trial results
% Why it failed in larger trials
% Lessons learned

\subsection{Other Immunomodulators}
% Corticosteroids
% Interferon
% Experimental agents

\section{Antiviral Medications}
\label{sec:antivirals}

\subsection{Valacyclovir and Acyclovir}
% For herpesvirus reactivation
% Evidence
% Dosing
% Patient selection

\subsection{Valganciclovir}
% For HHV-6, CMV
% Montoya study
% Risks and benefits

\subsection{Antiretroviral Approaches}
% Exploratory studies
% Rationale

\section{Mitochondrial Support}
\label{sec:mitochondrial-support}

\subsection{Coenzyme Q10 (CoQ10)}
% Ubiquinol vs. ubiquinone
% Dosing
% Evidence
% Bioavailability

\subsection{NADH}
% Role in energy production
% Studies in ME/CFS
% Dosing

\subsection{D-Ribose}
% ATP synthesis support
% Evidence
% Dosing protocols

\subsection{L-Carnitine and Acetyl-L-Carnitine}
% Fatty acid transport
% Mitochondrial function
% Evidence in ME/CFS

\subsection{Alpha-Lipoic Acid}
% Antioxidant properties
% Mitochondrial cofactor
% Dosing

\section{Neuroprotective and Cognitive Enhancers}
\label{sec:neuroprotective}

% Citicoline
% Phosphatidylserine
% Ginkgo biloba
% Evidence and limitations
